Original Research
Monday, November 13, 2023
01:00 PM–02:30 PM
Abstract
Introduction: Intestinal dysbiosis been demonstrated in chronic kidney disease (CKD) patients and has been considered as a contributor to disease progression due to over-production of proteolytic microbial uremic toxins. Hence, gut microbiota appeals to be a potential therapeutic target in CKD dietary management raising interest to investigate the potential role of various dietary fibers putting intestinal health into consideration.
Research Question or Hypothesis: This study is mainly directed to investigate the potential benefit of gum acacia as a gut-microbiota targeted therapeutic option in the management of chronic kidney disease.
Study Design: A parallel two-arms with 1:1 allocation, open-labelled randomized clinical trial was conducted in the period between July 2022 till April 2023
Methods:Patients aged > 18 years with stage 3 to 5 non-hemodialysis CKD (chronic kidney disease) were eligible for inclusion. Pregnancy, lactation, inflammatory bowel disease, malignancy and antibiotic consumption during the past month were recognized as exclusion criteria. Total 108 patients were eligible for inclusion and were randomly allocated into intervention (25 grams gum acacia daily) arm and control arm. Patients were followed up for 3 months. Primary outcomes were to assess difference in kidney function (urea, creatinine and glomerular filtration rate), serum levels of uremic toxins (p-cresyl sulfate (pCS) and indoxyl-sulfate (IS)) between baseline and follow up.
Results:A total of 80 patients completed the study. At baseline, both groups did not significantly differ in age or any other socio-demographic variables. After 12 weeks, intervention group showed a significant decrease in serum levels of both PCS and IS by 13.08% (P 0.0008) and 20.3% (P 0.001) respectively, while both levels of PCS and IS increased significantly in control group by 24.1 % (P 0.007) and 11.28% (P 0.01) respectively
Conclusion: To conclude, our study demonstrated the potentiality of gum acacia in reducing uremic toxin production, preserving kidney function and retarding the progression of CKD.
Presenting Author
Merna AbouKhatwa BSc of Clinical PharmacyFaculty of Pharmacy, Alexandria University
Authors
Noha Hamdy PhD of Clinical Pharmacy
Faculty of Pharmacy, Alexandria University
Ahmed Elkoraie PhD of Internal Medicine
Faculty of Medicine, Alexandria University
Samah Elsohafy PhD of Pharmacognosy
Faculty of Pharmacy, Alexandria University
Shaimaa Sallam PhD of Pharmacognosy
Faculty of Pharmacy, Alexandria University